Home
Clinical Resources Search
PQI: Selinexor (Xpovio®) Patient Management

Selinexor (Xpovio®) Patient Management

Download PQI pdf

Last Updated: November 14, 2023

By: Jeremiah Moore, PharmD

About this PQI

This PQI will provide background on the novel medication selinexor for patients with multiple myeloma (MM) who have received at least one prior therapy, relapsed, refractory multiple myeloma (RR-MM), and relapsed, refractory diffuse large b-cell lymphoma (RR-DLBCL) and discuss effective practices to maximize the use of selinexor therapy.

More About This PQI

PQI in Action Articles:

Selinexor_xpovio_patient_management pdf

How to Use a Positive Quality Intervention (PQI)

Essentially, it’s a tool to improve patient care by sharing best practices in oncology care.

Consider this standardized, peer-review clinical guidance to oncology healthcare teams, enabling you and your team to consistently deliver high-quality care to your patients.

Find a PQI

Find Similar Resources

All Resources

PQI PQI in Action PQI Podcast Toolkit Treatment Support Kit Video Diffuse Large B-Cell Lymphoma (DLBCL) Hematological Malignancies Lymphoma Multiple Meloma (MM) Multiple Myeloma Selinexor Xpovio

PQI

PQI: Retifanlimab-dlwr in Combination with CARBOplatin + PACLItaxel for the First-Line Treatment of Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal

Last Updated: 10/21/2026

PQI

PQI: Teclistamab-cqyv (Tecvayli) in Combination with Daratumumab and Hyaluronidase-fihj (Darzalex Faspro) for Relapsed Multiple Myeloma

Last Updated: 09/10/2026

PQI

PQI: Teclistamab-cqyv (Tecvayli) in Combination with Daratumumab and Hyaluronidase-fihj (Darzalex Faspro) for Relapsed Multiple Myeloma

Last Updated: 09/10/2026

Patient Education Sheet

PQI: Retifanlimab-dlwr in Combination with CARBOplatin + PACLItaxel for the First-Line Treatment of Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal

Last Updated: 10/21/2026

PQI

Frequently Searched

Supported by

Selinexor (Xpovio®) Patient Management

About this PQI

More About This PQI

PQI in Action Articles:

How to Use a Positive Quality Intervention (PQI)

Find Similar Resources

PQI: Retifanlimab-dlwr in Combination with CARBOplatin + PACLItaxel for the First-Line Treatment of Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal

PQI: Ruxolitinib Extended Release for the Management of Myelofibrosis, Polycythemia Vera, and Graft-Versus-Host Disease

PQI: Gedatolisib Combination Therapy for Locally Advanced or Metastatic Breast Cancer

PQI: Relacorilant (LIFYORLI) and Albumin-Bound Paclitaxel (Nab-Paclitaxel) for Platinum-Resistant Ovarian Cancer

PQI in Action: Inavolisib (Itovebi) Patient Management

PQI in Action: Revumenib (Revuforj) for the Management of Acute Leukemia

PQI in Action: Capivasertib (Truqap) Patient Management

PQI in Action: Sutimlimab-jome (Enjaymo) for the Management of Hemolysis in Cold Agglutinin Disease (CAD)

S11 E9: Keep Saying Yes: Living, Advocating, and Finding Purpose with Cancer

S11 E10: Fungi, Facts, and Cancer Care: Exploring Medicinal Mushrooms

S11 E8: The Future of Oncology

S11 E7: Your Health Story in One Place

Toolkit: Simplify CLL Tracking in Oncology Practices

Toolkit: Optimize CLL Care in Epic

Treatment Support Kit: Elranatamab

Treatment Support Kit: Bispecific (T-Cell Engager)

Treatment Support Kit: Zanidatamab-hrii

Treatment Support Kit: Avutometinib and Defactinib

Video: Akynzeo® (Ready-to-Use Vial): A Step-by-Step Video Guide

Video: Ibrutinib-Related Cardiac Toxicities: Management & Dose Modifications

Video: Neratinib for Extended Adjuvent Treatment of Adult Patients with Early-Stage HER2-Positive Breast Cancer (MIP)

Video: BRUKINSA® (Zanubrutinib) for Treatment of Relapsed or Refractory Marginal Zone Lymphoma

Up Close with Axicabtagene Ciloleucel

Up Close with Lisocabtagene Maraleucel

Up Close with Tisagenlecleucel

PQI: Tafasitamab-cxix (Monjuvi) for Relapsed/Refractory Follicular Lymphoma

S7 Ep 8: Sickle Cell Disease Insights

Dexamethasone, Etoposide, Ifosfamide, and Carboplatin

Nivolumab and Ifosfamide, Carboplatin, and Etoposide

Pemetrexed

Topotecan

Melphalan Conditioning for Autologous Transplant

Talquetamab, Pomalidomide and Daratumumab/Hyaluronidase

Talquetamab and Daratumumab/Hyaluronidase

PQI: Teclistamab-cqyv (Tecvayli) in Combination with Daratumumab and Hyaluronidase-fihj (Darzalex Faspro) for Relapsed Multiple Myeloma

PQI: Administration of Subcutaneous Isatuximab-irfc (SARCLISA ESCENA) via the CirCLIQ On-Body Delivery System

Isatuximab-irfc (SARCLISA ESCENA) with the CirCLIQ On-Body Delivery System: Treatment Discussion Guide

Melphalan Conditioning for Autologous Transplant

PQI: Teclistamab-cqyv (Tecvayli) in Combination with Daratumumab and Hyaluronidase-fihj (Darzalex Faspro) for Relapsed Multiple Myeloma

Selinexor

PQI in Action: Selinexor (Xpovio®)Patient Management

Selinexor

PQI in Action: Selinexor (Xpovio®)Patient Management

PQI: Retifanlimab-dlwr in Combination with CARBOplatin + PACLItaxel for the First-Line Treatment of Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal

PQI: Ruxolitinib Extended Release for the Management of Myelofibrosis, Polycythemia Vera, and Graft-Versus-Host Disease

Rusfertide (Mimrylo)

Lirafugratinib (Lyrfigtu)